The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved. · v2.0

Privacy PolicyTerms of UseCookie Policy

PRLD FINANCIAL STATEMENTS

Prelude Therapeutics Inc — balance sheet, income statement and cash flow trends

PRLDPrelude Therapeutics Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value itDuel
PriceFinancialsPeers

Income Statement

Quarterly progression — trailing-twelve-month values
RevenueNet Income to Owners
-100 M-50 M0202120222023202420252026

Profit Funnel

Q2 2026 · TTM
Revenue22.4 M $Gross Profit22 M $ · 98%Operating Income-67.4 M $ · -301%Pre-tax Income-60.5 M $ · -270%Net Income to Owners-60.5 M $ · -270%

Percentages are relative to revenue.

Key Figures

YoY change
Revenue22.4 M $+220.3%
Gross Profit22 M $+259.3%
Operating Income-67.4 M $—
EBITDA-58.9 M $—
Net Income to Owners-60.5 M $—

No peer data is available for this stock.

Balance Sheet

Quarterly period-end values
Total AssetsTotal LiabilitiesEquity
0200 M202120222023202420252026

Capital Structure

Q2 2026
Total Assets189.4 M
  • Equity133.7 M $71%
  • Current Liabilities38 M $20%
  • Long-term Liabilities17.6 M $9%

Key Figures

YoY change
Total Assets189.4 M $+64.8%
Total Liabilities55.6 M $+42.3%
Total Equity133.7 M $+76.3%
Cash & ST Investments151.8 M $+107.3%
Total Debt17.7 M $-1.5%
Net Debt-8.7 M $—

No peer data is available for this stock.

Cash Flow Statement

Quarterly progression — trailing-twelve-month values
Operating Cash FlowCapital ExpendituresFree Cash Flow
-100 M-50 M0202120222023202420252026

Cash Flow Bridge

Q2 2026 · TTM
-100 M-50 M0-33.3 M $Operating-77.3 M $Investing110.4 M $Financing-62 K $Net Change

Key Figures

YoY change
Operating Cash Flow-33.3 M $—
Capital Expenditures0 $-100.0%
Free Cash Flow-33.3 M $—
Dividends Paid——

No peer data is available for this stock.

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on PRLD

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Sep 11, 26. This content is for informational purposes only and is not investment advice.